GSK vs SBDS · P/E 13, $103.31B cap vs rev $151.3M
GlaxoSmithKline PLC ADR (GSK) versus Solo Brands, Inc. (SBDS) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Solo Brands, Inc. (SBDS) is a internet retail company listed on NYSE.
GSK does not have a complete income-statement cache yet.
Latest reported SBDS revenue for 2026-06-30 was $151.3M. Net income was -$9.9M. SBDS currently screens at market cap $10.0M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. SBDS currently screens at market cap $10.0M.
Not investment advice. Open the GSK and SBDS stock pages for the full models.
Not investment advice.